Medical weight loss is a program run by a licensed provider that combines prescription medication with lab monitoring and regular check-ins. BHRT Delivered offers it to Florida adults online and in person at our Palm Beach County clinic, using compounded semaglutide or tirzepatide.
Treatment may be appropriate for adults with:
A body mass index (BMI) of 30 or higher, or
A BMI of 27 or higher plus a weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or sleep apnea.
It suits people who have tried changing diet and activity and want medical support to go further. Medication works alongside those changes and does not replace them.
These medications are not suitable if you:
Have had medullary thyroid cancer, or it runs in your family
Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Are pregnant, planning pregnancy or breastfeeding
Tell your provider about any history of pancreatitis, gallbladder disease, kidney problems or diabetic eye disease, and about any diabetes medication you take.
Both are once-weekly injections you give yourself at home. Both reduce appetite and help you feel full sooner.
| Semaglutide | Tirzepatide | |
|---|---|---|
| How it works | Copies one gut hormone, GLP-1 | Acts on two gut hormones, GIP and GLP-1 |
| Average weight loss in trials of the brand-name product | About 15% of body weight over 68 weeks | About 15% to 21% over 72 weeks, depending on dose |
| Our monthly price | From $229 | From $299 |
| Learn more | Semaglutide | Tirzepatide |
We prescribe compounded semaglutide and tirzepatide, prepared by FarmaKeio and EVEXIAS. Compounded medications are not FDA-approved, and the compounded versions have not been through the trials above. Results vary from person to person.
Your provider will recommend one based on your health history, your goals and your budget.
Free 15-minute phone consultation. We review your weight history, health conditions and medications.
Lab testing. You choose where: at our clinic, at a Quest Diagnostics location near you, or with a mobile phlebotomist who comes to your home or office.
Your plan. A Florida-licensed provider decides whether medication is appropriate and which one fits you.
Delivery. Medication ships to your Florida address.
Gradual dose increases. You start low and step up about every four weeks, which keeps side effects down.
Follow-up. We retest at 90 days and at 6 months, then every 12 months. Your provider is available between tests.
Most people notice a smaller appetite within the first few weeks. Weight loss builds gradually over many months as the dose increases.
The most common side effects are nausea, diarrhea, constipation and stomach discomfort, mostly when starting or increasing the dose. Each medication page lists the less common, more serious risks.
Weight usually returns if the medication is stopped, so think of this as long-term treatment. Your provider can discuss maintenance.
Your first step is a free 15-minute phone consultation. There is no charge and no obligation.
If you decide to go ahead
Monthly membership
Compounded semaglutide starts at $229 per month and compounded tirzepatide at $299 per month, depending on your dose. That covers:
Membership is month to month. There is no minimum commitment, and you can cancel at any time.
We do not accept insurance for memberships. We accept HSA and FSA cards, and financing is available.
In a 2025 head-to-head trial of the brand-name products, average weight loss was larger with tirzepatide. Semaglutide has been in use longer and costs less. Your provider will help you choose.
Yes. Medication makes it easier to eat less, and the results are better and last longer with changes to eating and activity.
Often, yes. Your provider will advise on timing and dose.
Tell us. We treat patients with type 2 diabetes and manage their medications. Your provider will decide whether these medications are appropriate alongside your other treatment.
No. Membership is month to month, with no minimum commitment. You can cancel at any time.
No. We treat adults who live in Florida.
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021.
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 2022.
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). NEJM, 2025.
